The estimated Net Worth of Mark Andrew Wilson is at least $1.51 Million dollars as of 19 August 2024. Mr Wilson owns over 5,651 units of Nektar Therapeutics stock worth over $281,579 and over the last 4 years he sold NKTR stock worth over $448,482. In addition, he makes $780,492 as Sr. VP and Gen. Counsel & Sec. at Nektar Therapeutics.
Mr has made over 19 trades of the Nektar Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 5,651 units of NKTR stock worth $7,233 on 19 August 2024.
The largest trade he's ever made was selling 8,690 units of Nektar Therapeutics stock on 16 November 2022 worth over $31,023. On average, Mr trades about 3,953 units every 68 days since 2020. As of 19 August 2024 he still owns at least 225,263 units of Nektar Therapeutics stock.
You can see the complete history of Mr Wilson stock trades at the bottom of the page.
Mark A. Wilson is the Sr. VP, Gen. Counsel & Sec. at Nektar Therapeutics.
As the Sr. VP and Gen. Counsel & Sec. of Nektar Therapeutics, the total compensation of Mr Wilson at Nektar Therapeutics is $780,492. There are 9 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
Mr Wilson is 49, he's been the Sr. VP and Gen. Counsel & Sec. of Nektar Therapeutics since . There are 12 older and 5 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Mark's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: